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The interferon (IFN)-λ family of type III cytokines includes the closely related interleukin 
(IL)-28A (IFN-λ2), IL-28B (IFN-λ3), and IL-29 (IFN-λ1). They signal through the Janus
kinases (JAK)-signal transducers and activators of transcription pathway and promote 
an antiviral state by the induction of expression of several interferon-stimulated genes 
(ISGs). Contrary to type I IFNs, the effect of IFN-λ cytokines is largely limited to epithelial 
cells due to the restricted pattern of expression of their specific receptor. Several genome-
wide association studies have established a strong correlation between polymorphism in 
the region of IL-28B gene (encoding for IFN-λ3) and both spontaneous and therapeutic 
IFN-mediated clearance of hepatitis C virus (HCV) infection, but the mechanism(s) under-
lying this enhanced viral clearance are not fully understood. IFN-λ3 directly inhibits HCV 
replication, and in vitro studies suggest that polymorphism in the IFN-λ3 and its recently 
identified overlapping IFN-λ4 govern the pattern of ISGs induced upon HCV infection of 
hepatocytes. IFN-λ can also be produced by dendritic cells, and apart from its antiviral action 
on hepatocytes, it can regulate the inflammatory response of monocytes/macrophages, 
thus acting at the interface between innate and adaptive immunity. Here, we review the 
current state of knowledge about the role of IFN-λ cytokines in mediating and regulating 
the immune response during acute and chronic HCV infections.
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iNTRODUCTiON
The interferon (IFN)-λ family of cytokines was first described in 2003 by two independent groups (1, 
2). By using computational analysis of unknown genes potentially corresponding to cytokines that 
were related to interleukin (IL)-10 and type I IFNs, Sheppard et al. identified three new cytokines, 
IL-28A, IL-28B, and IL-29 (2). Expression of these three cytokines could be induced in peripheral 
blood mononuclear cells (PBMCs) and other cell types upon poly I:C stimulation or viral infection. 
Furthermore, these cytokines demonstrated antiviral activity and were shown to bind to a new 
receptor, IL-28Rα, that forms a heterodimer with IL-10R2. Around the same time, Kotenko et al. 
also identified three new genes related to the IFN type I and IL-10 families (1). The new cytokines 
were named IFN-λ1, IFN-λ2, and IFN-λ3 (equivalent to IL-29, IL-28A, and IL-28B, respectively). 
The newly described cytokines were shown to bind to a new receptor complex composed of IFN-λR1 
(equivalent to IL-28Rα) and the IL-10R2, signal through the Janus kinases-signal transducers and 
activators of transcription (Jak-STAT) pathway, and exhibit antiviral activities via the induction of 
interferon-stimulated genes (ISGs) and upregulation of major histocompatibility complex (MHC) 
class I. In 2013, a dinucleotide frameshift variant rs368234815 (previously termed ss469415590) 
Table 2 | Type iii iFN gene polymorphisms.
SNP Common 
name
alternative  
names
Favorable 
allele
Unfavorable 
allele
rs12979860 IFN-λ3 IL-28B CC TT
IFNL4 rs12979860
rs8099917 IFN-λ3 IL-28B TT GG
rs368234815 IFN-λ4 ss469415590 TT ΔG
rs117648444 IFN-λ4-
P70S
AA 
(IFN-λ4-S70)
GG 
(IFN-λ4-P70)
Table 1 | Type iii iFN genes and proteins.
Gene alternate gene 
names
Protein alternate protein 
names
Receptor IFNLR1 IL-28RA, IL-28R1, 
IFNLR
IFN-λR1 IL-28RA, IL-28Rα, 
IL-28R1
Cytokines IFNL1 IL-29 IFN-λ1 IL-29
IFNL2 IL-28A IFN-λ2 IL-28A
IFNL3 IL-28B IFN-λ3 IL-28B
IFNL4 – IFN-λ4 –
2
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(TT or ΔG) was identified in the IFN-λ region. This frameshift 
variant was shown to create a novel gene, IFNL4, encoding the 
IFN-λ4 protein (3). This new protein was related to IFN-λ3 (29.1% 
identity and 40.8% similarity between both proteins). Expression 
of IFN-λ4 activated the Jak-STAT pathway and resulted in the 
expression of ISGs (3). In this article, we will use the nomenclature 
of IFN-λ genes, protein, and polymorphisms according to the 
Human Genome Organization Gene Nomenclature Committee. 
Alternative names for IFN-λ genes and proteins (including IFN-λ 
specific receptor) are listed in Table 1.
TiSSUe TROPiSM OF TYPe i veRSUS 
TYPe iii iFNs
Type I and type III IFNs are related and may act in parallel via 
the same pathways. Type I IFNs (IFN α/β) can act on multiple 
cell types and tissues because their specific receptors (IFNAR1 
and IFNAR2) are ubiquitously expressed. In contrast, IFN-λR1 
expression is rather restricted and as such it affects a much more 
limited set of cells and exhibits reduced side effects (4). IFN-
λR1 is mostly expressed by cells of epithelial origin including 
hepatocytes (5, 6). However, its expression on hematopoietic cells 
remains controversial. This issue is discussed in more detail below, 
but it is generally believed that the main immune cells expressing 
IFN-λR1 are dendritic cells (DCs) (4, 7, 8). Most studies assessed 
the expression of IFN-λR1 by polymerase chain reaction (PCR), 
evaluating the mRNA level, which might not accurately reflect 
expression of the protein on cell surface. It was demonstrated 
that immune cells [B cells, T cells, and natural killer (NK) cells] 
express mostly a shorter splice variant of IFN-λR1 that can be 
secreted (9). This secreted form could bind IFN-λ with moderate 
affinity and inhibit its effects. This could explain at least in part 
why immune cells express IFN-λR1 mRNA but lack responsive-
ness to IFN-λ treatment.
aSSOCiaTiON OF TYPe iii iFN 
POlYMORPHiSMS wiTH HCv 
SPONTaNeOUS CleaRaNCe aND 
ReSPONSe TO iFN THeRaPY
Hepatitis C virus (HCV) infection is a global health problem. 
Only 25% of individuals acutely infected with HCV are able to 
eliminate the virus spontaneously, while the majority (~75%) 
develops persistent infection and chronic liver disease including 
fibrosis, cirrhosis, and liver cancer (10). Until 2011, the only 
available treatment for HCV was a combination of ribavirin and 
pegylated IFN-α (11). This non-specific treatment was modestly 
effective, especially in individuals infected with genotype 1, 
resulting in ~50% sustained virological response (SVR) rate 
defined as undetectable viral load 24  weeks following the end 
of treatment (12). Furthermore, the course of treatment was 
long (48  weeks) and associated with multiple side effects, thus 
significantly impacting the quality of life of the patients (13). 
Factors associated with higher odds of spontaneous resolution 
or response to IFN therapy include virus genotype, gender, and 
ethnicity, suggesting that genetic factors are key determinants of 
viral clearance (14, 15). Individuals of European ethnicities were 
more likely to achieve SVR compared to individuals of African 
ancestry (14, 16). These differences accompanied by the difficul-
ties and side effects associated with IFN treatment prompted 
research into genetic factors that can predict SVR. Several 
genome-wide association studies demonstrated a link between 
single-nucleotide polymorphisms (SNP) near the IFNL3 gene 
encoding IFN-λ3 and HCV infection outcome and response to 
treatment. These major polymorphisms are listed in Table 2. Ge 
et al. demonstrated that the IFN-λ3 rs12979860 SNP predicted 
the response to IFN treatment in an American cohort composed 
of multiple ethnicities infected with HCV genotype 1 (17). The 
favorable allele (CC genotype) was not only overrepresented in 
the treatment responder group but was also more prevalent in the 
European population compared to the African population where 
the unfavorable TT genotype was more prevalent. Moreover, the 
IFN-λ3 rs12979860 genotype was a better predictor of treatment 
outcome than ethnicity, since African Americans with the CC 
genotype were more likely to achieve SVR than the European 
American bearing the TT genotype (17). That study also demon-
strated that the CC genotype was associated with higher baseline 
viral loads in all groups tested. Two other studies confirmed 
the same association with polymorphism in the IFN-λ3 region 
in Australian (18) and Japanese cohorts (19) and identified an 
additional SNP (rs8099917). This SNP was associated with HCV 
genotype 1 treatment response in the Australian cohort and 
confirmed with other cohorts (18). This study also used quan-
titative reverse transcription PCR to demonstrate that healthy 
individuals carrying the favorable allele (TT) expressed higher 
levels of IFN-λ2 and IFN-λ3 transcripts in peripheral blood. In 
the Japanese cohort, both SNPs (rs12979860 and rs8099917) were 
associated with treatment response (19).
The favorable rs12979860 CC genotype was also associated 
with spontaneous clearance in untreated individuals from six 
different cohorts (20). In this study, Thomas et al. also observed 
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that the C allele was more represented in Europeans compared 
to African individuals. More importantly, they demonstrated 
that the C allele was associated with spontaneous resolution of 
HCV infection in both ethnic groups. Moreover, the protective 
effect appeared to be recessive, since there was no difference 
between heterozygous individuals bearing the CT genotype and 
homozygous individuals bearing the TT genotype. This study 
also genotyped >2,000 individuals worldwide and demonstrated 
that the C allele was most prevalent in East Asia, whereas the T 
allele was most prevalent in Africa and an intermediate pattern 
with both alleles was observed in Europe. Similar results were 
obtained by Rauch et al. who sequenced the IFN-λ3 rs8099917 
SNP and showed association of the unfavorable allele with 
establishment of a chronic infection and treatment failure in 
HCV monoinfected and HCV/HIV coinfected individuals (21). 
Finally, the IFN-λ3 rs12979860 SNP was also associated with 
spontaneous clearance and jaundice in a single-source cohort 
(22). The German anti-D cohort consists of 2,867 women who 
were exposed to HCV genotype 1b after treatment with anti-D 
immunoglobulin. Fifty-two percent of infected women achieved 
spontaneous clearance. This cohort enabled the evaluation of the 
role of IFN-λ3 polymorphism in spontaneous clearance without 
the confounding effect of virus genetics. In this cohort, it was 
possible to analyze genetic factors associated with spontaneous 
clearance in 190 women. Results demonstrated that spontaneous 
clearance was strongly associated with the IL-28B/IFN-λ3 geno-
type (22). The highest rate of clearance was observed in women 
homozygous for the favorable C allele (CC, 64.2% clearance), the 
lowest rate of clearance was observed in women homozygous for 
the unfavorable T allele (TT, 6.1% clearance), and intermediate 
levels of clearance were observed in heterozygous women (CT, 
24.4% clearance) (22). IFN-λ3 favorable genotype was also asso-
ciated with clearance upon reinfection in high-risk people who 
inject drugs (23).
In 2013, a new dinucleotide polymorphism rs368234815 
(previously termed ss469415590) located near the IFNL3 gene 
was identified, and the variants TT or ΔG were associated with a 
frame shift resulting in either production of a new protein, IFN-
λ4, (ΔG) or absence of the protein due to the introduction of a 
frameshift creating an early stop codon (TT) (3, 24). This new 
polymorphism was in high linkage disequilibrium with the IFN-
λ3 rs12979860 polymorphism and was found to be a stronger 
predictor of HCV spontaneous resolution and treatment outcome 
of chronic HCV (3, 25, 26). Another group reported association 
of the TT/ΔG polymorphism with HCV treatment outcome in a 
large European cohort (27). Given that the IFN-λ3 rs12979860 
was located within the newly discovered IFN-λ4 region, it was 
suggested to change its nomenclature to IFN-λ4 rs12979860 (24).
MeCHaNiSMS UNDeRlYiNG THe ROle 
OF iFN-λ POlYMORPHiSMS iN HCv 
CleaRaNCe
The exact mechanisms underlying the role of IFN-λ polymor-
phisms in HCV clearance are not well understood. It was pro-
posed that such polymorphisms may influence the expression of 
IFN-λ cytokines during HCV infection and their downstream 
effects on expression of ISGs and innate and adaptive immune 
cells. Although it was demonstrated early on that IFN-λ SNPs 
may influence expression of the IFN-λ transcripts in PBMCs (18), 
data evaluating the circulating levels of IFN-λ cytokines during 
acute and chronic HCV were inconclusive. Data from the chimp 
model of HCV infection demonstrated that type III IFNs were 
strongly induced upon HCV infection at the gene and protein 
level and correlated with ISG expression and viral load (28). In 
humans, while some studies associated the favorable IFN-λ3 CC 
allele with higher serum levels of IFN-λ (29), others demonstrated 
the reverse correlation (7). One report also found no difference 
in serum levels of IFN-λ between HCV treatment responders and 
non-responders (30). Our group has demonstrated that serum 
levels of IFN-λ3 were highly variable, but were lower in individu-
als bearing the favorable IFN-λ3 CC allele (31). Altogether, type 
III IFN genotyping has been, so far, a more accurate predictor for 
HCV infection or treatment outcome compared to the circulating 
levels of the cytokines.
How the expression of IFN-λ4 would interfere with HCV 
clearance or treatment response is not fully understood. It 
was shown that the protein is only poorly secreted (3, 32). 
Nevertheless, the protein could interact with the same receptor 
as IFN-λ3 (IFN-λR1 and IL-10R2) and displayed similar levels of 
activation of ISGs and antiviral activity (32). It remains possible 
that IFN-λ4 has other functions apart from activation of ISGs, 
perhaps through the interaction with an intracellular receptor. 
Both IFN-λ3 and IFN-λ4 polymorphisms were associated with 
the level of expression of the type I IFN receptor IFNAR1 in 
PMBCs (33). Individuals carrying both favorable alleles expressed 
the highest level of IFNAR1, while individuals bearing both unfa-
vorable alleles exhibited lower levels. Treatment of PBMC with 
IFN-α confirmed that individuals with both favorable alleles and 
the highest IFNAR1 expression also exhibited the highest ISG 
induction.
Several early studies demonstrated a link between the liver 
expression levels of ISGs before IFN treatment initiation and 
treatment outcome (34–37). A higher level of expression of a set of 
ISGs and genes involved in IFN regulatory pathways (ISG15 and 
USP18) was observed in non-responder patients before treatment 
and predicted treatment outcome (34). Furthermore, the level of 
expression of several ISGs was shown to correlate with IFN-λ 
genotypes, with the unfavorable alleles associated with higher 
hepatic levels of ISGs (37, 38). Unphosphorylated IFN-stimulated 
gene factor 3 (ISGF3) is induced by type III IFNs and sustains 
expression of USP18, a negative regulator of IFN signaling, result-
ing in unresponsiveness to IFN-α treatment (39). Comparison of 
levels of ISGs before and after treatment further demonstrated 
that the high basal expression levels in non-responders did not 
increase above pretreatment level, whereas there was a strong ISGs 
induction in the SVR group (40). This suggests that the baseline 
high ISG levels in non-responders render them unresponsive to 
further IFN stimulation upon therapy. Extending this hypothesis 
to explain why the expression of IFN-λ4 would be detrimental for 
HCV infection and treatment outcome, patients expressing a less 
active variant of the IFN-λ4 protein had better odds of achieving 
spontaneous clearance or SVR (41). This study demonstrated that 
FiGURe 1 | interferon (iFN)-λ polymorphisms are associated with hepatitis C virus (HCv) spontaneous resolution and response to treatment. (a) In 
HCV acutely infected individuals, IFN-λ3 rs12979860 CC and IFN-λ4 rs368234815 TT favorable alleles are strongly associated with spontaneous resolution. 
Hepatocyte infection triggers the production of IFN-λ that then induce the expression of hundreds of interferon-stimulated genes (ISGs). In individuals carrying the 
favorable alleles, production of IFN-λ is moderate, and the ISGs induction is more focused, leading to an effective antiviral state and increased rate of spontaneous 
resolution of infection. On the other hand, carriers of the unfavorable alleles exhibit stronger IFN-λ production and a more diverse array of ISGs can be detected. 
This will also induce the expression of USP18, an inhibitor of the IFN signaling pathway, leading to an impaired antiviral state and an increased rate of chronic HCV 
infection. (b) In chronically infected individuals carrying the favorable allele, basal level of IFN-λ and ISGs is relatively low and treatment with IFN-α can induce a 
potent antiviral state leading to viral clearance or SVR. In individuals carrying the unfavorable allele, a high basal level of IFN-λ, ISGs, and USP18 will lead to a 
refractory state and unresponsiveness to the IFN-α treatment and failure to clear the infection.
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the IFN-λ4-S70 protein (SNP rs117648444) exhibited reduced 
ISG activation and antiviral activity in  vitro. When comparing 
infection and treatment outcome in a large cohort, individuals 
bearing genetic variants resulting in no IFN-λ4 production had 
the highest odds of clearance/SVR, followed by those expressing 
the IFN-λ4-S70 impaired protein and finally those expressing the 
IFN-λ4-P70 fully active protein had the lowest odds of achieving 
clearance/SVR.
On the basis of current knowledge, we can elaborate a model 
where during acute HCV infection, innate immune responses 
are induced in hepatocytes that trigger the production of type III 
cytokines that stimulate a variety of antiviral ISGs. In individu-
als carrying the favorable IFN-λ3 rs12979860 CC and IFN-λ4 
rs368234815 TT alleles, production of IFN-λ is controlled, and 
the induction of ISGs is more focused leading to an effective 
antiviral state and increased rate of spontaneous resolution of 
infection. In contrast, carriers of the unfavorable alleles exhibit 
stronger IFN-λ production and a more diverse array of ISGs. This 
will also induce the expression of USP18, an inhibitor of the IFN 
signaling pathway, leading to an impaired antiviral state and to an 
increased propensity to develop chronic infection. This effect is 
not absolute, and some individuals carrying the favorable alleles 
will develop chronic infection. In chronically infected individuals 
carrying the favorable allele, basal levels of IFN-λ and ISGs will 
be relatively low and treatment with IFN-α can induce a potent 
antiviral state leading to viral clearance or SVR. In individuals 
carrying the unfavorable allele, a high basal level of IFN-λ, ISGs, 
and USP18 will lead to a refractory state and unresponsiveness 
to the IFN-α treatment, and failure to respond to treatment 
(Figure 1).
TYPe iii iFNs aND iNNaTe iMMUNiTY iN 
THe liveR
HCV is a hepatotropic infection and investigation of the early steps 
of viral replication, and the innate immune response is hindered 
by the difficulty to access the infected tissue, i.e., the liver. In vitro 
systems usually show low level of viral replication, and animal 
models to study the immune response are limited to chimpanzees 
that are no longer used in research. Thus, limited information 
is available about the activation of the innate immune response 
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in the liver of HCV-infected individuals during acute infection. 
Nevertheless, chimpanzee data have demonstrated strong induc-
tion of ISGs in the liver early after infection irrespective of the 
outcome toward resolution or chronicity (42, 43). Examining the 
kinetics of type I versus type III IFNs demonstrated that HCV-
infected chimpanzees exhibited rapid induction of type III IFNs 
in the liver. This was associated with upregulation of ISGs but 
minimal induction of type I IFNs (44). Similarly, infection of 
primary human hepatocytes (PHHs) induced production of type 
III IFNs that were associated with induction of a distinct set of 
ISGs compared to type I IFNs (44, 45). Sheahan et al. used PHHs 
and laser capture microdissection to compare the transcriptional 
profile of HCV-infected hepatocytes to adjacent uninfected cells 
(46). They demonstrated that infected cells had a transcriptional 
profile dominated by innate immunity genes, including induc-
tion of IFN-λ genes only in infected cells. Interestingly, when 
comparing gene expression from donors of different IFN-λ 
genotypes, they demonstrated that even if a greater number of 
genes were induced in the unfavorable (TT) allele group, the 
response in the favorable allele group (CC) was more focused 
toward antiviral and cell death responses, and unsurprisingly, 
viral replication was more limited in donors bearing the favora-
ble allele (46). Onabajo et  al. also used an in  vitro system of 
PHHs and hepatic cells and demonstrated that IFN-λ4, while 
highly retained inside cells, is also secreted and induces strong 
ISGs response in surrounding cells, including the expression 
of IP-10 (47). However, IFN-λ4 expression was associated with 
reduced proliferation and increased cell death (47). Ferraris et al. 
used PHHs of different IFN-λ3/4 genotypes to investigate the 
mechanisms associated with HCV clearance (48). Treatment of 
HCV-infected cells with either IFN-α or IFN-λ1 decreased viral 
load only in cultures carrying the favorable IFN-λ3/4 alleles (48). 
They also showed that, in both PHHs and liver biopsies of HCV-
infected subjects, IFN-λ1, IFN-λ3, and ISGs production were 
higher in carriers of the unfavorable allele. Silencing of IFN-λ1 
in unfavorable allele context restored IFN-α antiviral activity, 
suggesting that the high basal IFN-λ and ISG expression blocked 
further activation by IFN-α treatment (48). The unresponsive-
ness observed in the context of the unfavorable IFN-λ3/4 alleles 
was shown to be driven by upregulation of USP18 (39). In liver 
biopsies from individuals with chronic HCV, it was also shown 
that the favorable IFN-λ4 rs368234815 TT genotype was associ-
ated with increased degranulation capacity (CD107a+) from T, 
NK, and NKT cells, which correlated with serum ALT and AST 
levels (49). This suggests increased innate immune activation in 
the livers of these individuals.
Hepatocytes are not the only source of type III IFNs in the 
liver. Hepatic stellate cells (HSC), normally in a quiescent state, 
become activated following liver damage induced by HCV infec-
tion and may modulate intrahepatic immune responses. HSCs 
activated with the TLR-3 ligand poly I:C exhibit an antiviral 
effect when co-cultured with HCV-infected hepatocytes (50). 
Supernatants of activated HSCs demonstrated an antiviral effect 
that could be blocked by antibodies specific to the IL-10R2. These 
in vitro results strongly suggest that HSCs can participate in the 
innate immune response in the liver via the production of IFN-λ. 
Finally, DCs can also act as a key source and regulator of type III 
IFNs in the liver and the peripheral blood.
iFN-λ iNTeRaCTiON wiTH 
HeMaTOPOieTiC CellS
The interaction of type III IFNs with hematopoietic cells is not 
fully understood. In contrast to type I IFNs whose receptors are 
ubiquitously expressed, type III IFNs have a limited number 
of target cells, because their receptor (IFN-λR1 and IL-10R2 
heterodimer) expression is highly restricted to the cells of epi-
thelial origin including hepatocytes and few hematopoietic cells 
(4–7). Although, IFN-λR1 transcripts could be detected in several 
hematopoietic cells, it has been problematic to detect its expres-
sion on cell surface. It has also been reported that hematopoietic 
cells may express a soluble splice variant that may influence their 
capacity to respond to type III IFNs (9, 51). In the following 
sections, we will discuss in details the effect of type III IFNs on 
different types of hematopoietic cells.
Monocytes and Macrophages
It was shown that IFN-λR1 was expressed on monocyte-derived 
macrophages, but not monocytes (52). Monocyte-derived mac-
rophages responded to IFN-λ1 treatment by phosphorylation 
of STAT-1 and increased production of cytokines such as tumor 
necrosis factor (TNF), IL-10, and IL-12p40 following TLR stimu-
lation. Similar effects were observed after treatment with IFN-λ2 
or IFN-λ3. Furthermore, contrary to IFN-α, IFN-λ1 enhanced 
cell surface expression of IFNGR1 on monocyte-derived mac-
rophages, thus enhancing IL-12p40 and TNF production after 
stimulation with IFN-γ (52). Polymorphism in the IFN-λ3 SNP 
rs12979860 also impacted the activation of monocytes where 
individuals of the TT unfavorable genotype produced lower 
levels of IL-12 upon activation of their monocytes with the TLR 
ligand R848 (53). Thus, a better IFN-λ response could potentiate 
the antiviral and inflammatory response of monocytes and may 
indirectly mediate viral clearance by boosting the induction and 
priming of the adaptive immune response.
NK Cells
Cytotoxic and antiviral functions of NK cells depend on a tightly 
regulated balance between activation and inhibitory signals. The 
main inhibitory mechanism is via binding of the killer cell-Ig-like 
receptors (KIR) with MHC class I molecules (54). The polymor-
phism within the KIR and MHC class I genes results in interac-
tions of different strengths and degrees of activation of NK cells 
that correlate with HCV infectious outcome (55). IL-28B/IFN-λ3, 
HLA-C, and KIR variants could additively predict response to 
IFN therapy in chronic HCV, suggesting a collaborative effort 
between type III IFNs and NK cells during viral clearance (56). 
Activation of NK cells, associated with the success of IFN-based 
treatment, was studied in relation to IFN-λ3 polymorphism, 
and patients carrying the unfavorable IFN-λ3 allele expressed 
higher levels of expression of the inhibitory receptor NKG2A on 
NK cells and were more likely not to respond to treatment (57). 
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These observations further underscored the potential effect of 
type III IFNs on NK cells.
In the context of acute infection, KIR2DS3 and the IFN-λ3 
SNP rs12979860 unfavorable T allele synergized to increase the 
risk of chronic infection (58). This study also suggested a direct 
link between IFN-λ and NK cells, showing reduced IFN-γ pro-
duction by NK cells upon IFN-λ treatment (58). However, these 
data were difficult to reproduce in other cohorts. The IFN-λ3 
rs12979860 CC genotype was associated with decreased levels of 
the inhibitory receptor NKG2A after infection resolution (31). 
Individuals bearing the CC genotype also displayed increased 
NK cell function measured by IFN-γ production after stimula-
tion irrespective of infectious outcome suggesting that IFN-λ 
genotype influenced NK cell function but that this was not suf-
ficient to achieve spontaneous HCV clearance (31). Although 
IFNLR1 mRNA expression could be detected in NK cells (59, 60), 
they express very low levels of the specific type III IFN receptor 
(IFN-λR1) on cell surface, even after IFN-α stimulation (31, 61, 
62). Treatment of purified NK cells with IFN-λ had no effect on 
neither NK cytotoxicity nor cytokine production (31, 60, 62, 63). 
On the other hand, it was reported that the level of expression 
of IFN-λR1 could be upregulated by IFN-λ treatment (59) and 
studies in IFN-λR1−/− mice have demonstrated that this receptor 
is required for optimal antitumoral in vivo activity of NK cells 
(64), suggesting that in some activation context, NK cells could 
become sensitive to type III IFNs.
Given the lack of activation of NK cells by IFN-λ (31, 60, 
62, 63), indirect mechanism were investigated. IFN-λ1 affected 
NK cells indirectly via the activation of monocyte derived 
macrophages. Macrophages activated by IFN-λ1 produced 
cytokines of the IL-12 family (IL-12p40) that could then 
activate NK cells leading to increased IFN-γ production. This 
activation was determined by polymorphisms in the IFN-λ3 
gene, and the presence of monocytes was essential (53). This 
suggests that HCV-infected individuals bearing the unfa-
vorable IFN-λ3 allele have an impaired monocyte function. 
Monocytes can activate NK cells through the production of 
IL-12 or IL-18. Stimulated monocytes from CC genotype back-
ground produced significantly more IL-12p40 and IL-12p70 
compared to monocytes of the CT or TT genotype. Blocking 
IL-12 and not IL-18 abolished the IFN-λ association with the 
level of NK cell activation by monocytes, suggesting that IL-12 
is a major player in the interplay between monocyte and NK 
cells that is associated with IFN-λ3 genotype in HCV-infected 
subjects (53).
Analysis of NK cell phenotype and function in chronic HCV 
infection demonstrated that CD56bright NK cell subsets are sig-
nificantly more cytotoxic than in healthy donors based on TRAIL 
and CD107a expression (65). This effect was independent of the 
IFN-λ3 rs12979860 genotype, but subjects carrying the TT geno-
type exhibited the highest levels of TRAIL+ and CD107a+IFN-
γ+NK cells. In the same study, CD56dim NK cells of TT genotype 
individuals produced more TNF-α. Accordingly, individuals with 
the TT genotype also had a higher proportion of polyfunctional 
NK cells (65).
In conclusion, whether by a direct or indirect mechanism, 
it appears that type III IFNs can modulate NK cells activation 
and functions but further investigation is required to identify the 
exact mechanism.
Dendritic Cells
Dendritic cells are important antigen-presenting cells and 
have a central role in mediating the link between the innate 
and adaptive immune response. DCs also are a major source 
of type III IFNs (8, 60, 66). Stimulation of DCs (in  vitro and 
ex vivo) with HCV RNA induced the production of both type 
I and type III IFNs and the levels were associated with IFN-λ3 
rs12979860 genotype, with the favorable CC allele leading to 
the highest IFN type III production (66). Type I and type III 
IFNs produced by DCs could control HCV replication in vitro, 
suggesting again an important role for type III IFN in HCV 
infection (66). During chronic HCV infection, serum levels of 
IFN-λ1 were lower compared to HCV resolvers and healthy 
controls (29). In acute HCV infection, IFN-λ1 serum levels 
were variable as described earlier (29, 31). Interestingly, HCV 
proteins E2 and NS3 inhibited IFN-λ1 production by stimulated 
DCs, suggesting that IFN-λ1 is an important immune mediator 
in HCV infection (29). On the other hand, treatment of DCs 
with IFN-λ altered their function toward a dysfunctional help 
to T cells (7). IFN-λ-treated DCs exhibited decreased T cell 
stimulation capacity by upregulating PDL1 expression. In addi-
tion, IFN-λ-treated DCs promoted the expansion of regulatory 
T cells (Tregs), further impeding with the immune response. 
Further research will be needed to clarify the role of IFN-λ and 
DCs during a viral infection, such as HCV.
CD4 and CD8 T Cells
The link between IFN-λ and T cells is less studied compared to 
the link with cells of the innate immune response. A study by Bes 
et al. showed that CD4 T cell responses to HCV, assessed by IFN-
γ enzyme-linked immunospot (ELISpot) assay, were of a higher 
frequency in the unfavorable allele (non CC) group (67). This was 
unexpected since a stronger immune response is normally associ-
ated with HCV spontaneous clearance. However, they tested a 
limited number of patient (n = 69; with 38 samples with positive 
ELISpot response), and there was a lot of variability between sam-
ples. In a more recent study, Scheurich et al. tested the breadth and 
frequency of CD4 responses to HCV and stratified their results 
according to the IFN-λ3 rs12979860 genotype (68). However, they 
did not find any difference between the various IFN-λ groups. 
Genetics studies showed that polymorphisms of MHC class I and 
MHC class II are associated with spontaneous clearance of HCV 
infection, independently of the IFN-λ3 polymorphism (69, 70). 
Protective alleles were shown to have additive effect, suggesting 
that innate and adaptive immunity contribute independently 
to the prediction of a favorable outcome following acute HCV 
infection. However, these independent associations do not rule 
out the possibility that type III IFN could modulate CD4 T cells 
responses. Indeed, data from other models suggest that IFN-λ 
can indeed impact CD4 T cells (71–73). It was reported that naive 
and memory CD4 T cells express IFN-λR1 mRNA and that T 
cell stimulation in presence of IFN-λ inhibited IL-4, IL-5, and 
IL-13 production, thus impeding the development of Th2 helper 
response without affecting cell proliferation (72, 73). IFN-λ also 
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inhibited the upregulation of IL-4Rα on the surface of stimulated 
naive CD4 T cells, thus limiting the Th2 polarizing effect of IL-4 
on these cells. IFN-λ-treated cells expressed significantly less 
GATA3, the transcription factor that is master regulator of Th2 
differentiation, further supporting the hypothesis that IFN-λ 
has inhibitory effect on the development of a Th2 response (73). 
Whether such mechanisms are implicated during HCV infection 
remains to be seen. It is also tempting to speculate that the effect 
of IFN-λ polymorphism on production of IL-12 by monocytes 
may indirectly influence priming of the HCV-specific CD4 and 
CD8 T cells and the generation of antiviral Th1 responses.
b Cells
The role of the B cells and neutralizing antibody responses during 
acute HCV infection remains unclear. Some studies showed that 
early anti-HCV antibody response is associated with higher rate 
of spontaneous clearance of the virus during primary infection 
and reinfection (74–78), but other studies showed no association 
(79–82). To our knowledge, no data are currently available on the 
role of IFN-λ polymorphisms in the B cell response against HCV 
but it can be inferred from other models. Generally, the role of 
IFN-λ on B cells was only modestly studied. One recent article by 
de Groen et al. demonstrated that both naive and memory B cells 
express IFNLR1 mRNA and that IFN-λ1 can activate B cells (83). 
Treatment of B cells with IFN-λ1 led to increased expression of 
ISGs (Mx1 and OAS1) as well as increased expression of TLR7. 
IFN-λ1 also enhanced IgM and IgG production from TLR7/8-
stimulated B cells. Finally, IFN-λ1 stimulation increased the 
proliferation of B cells stimulated with TLR7/8 agonist. However, 
after TLR2 or TLR9 stimulation, IFN-λ1 had no effect on the 
antibody production or proliferation (83). Globally, this study 
suggests that IFN-λ1 can enhance B cell response, but only under 
certain stimulation conditions.
In another context, Egli et al. showed that the IFN-λ3 rs8099917 
GG genotype was associated with a higher rate of seroconversion 
after influenza vaccination in a cohort of immune-suppressed 
transplant patients (84). In addition, GG genotype carriers 
showed lower Th1 responses after PBMC stimulation with influ-
enza antigens, suggesting that the IFN-λ3 rs8099917 genotype 
can affect the Th1/Th2 balance. Accordingly, adding IFN-λ3 in 
the stimulation medium increased the Th1 cytokine production 
and reduced Th2 cytokine production (84). These observations 
were confirmed in a cohort of healthy volunteers where IFN-λ3 
treatment enhanced Th1 cytokine profile and reduced produc-
tion of Th2 cytokines after influenza stimulation (84). Also, 
IFN-λ3 decreased B cell proliferation and antibody production. 
Interestingly, it was also demonstrated that adding peptides 
that block the effect of IFN-λ3 during the stimulation led to an 
increased antibody production, suggesting that blocking IFN-λ3 
during influenza vaccination could improve the seroconversion 
rate and thus have a better protective effect (84).
These two aforementioned studies used different type III 
IFNs to stimulate B cells (IFN-λ1 or IFN-λ3) as well as different 
antigenic stimulation. Hence, there is no clear conclusion on 
whether type III IFNs exert a beneficial or detrimental effect on 
B cell function and antibody production, and additional studies 
with standardized stimuli are warranted.
SUMMaRY OF THe ROle OF TYPe iii iFNs 
ON HeMaTOPOieTiC CellS
Within the hematopoietic compartment, DCs are the main 
producers of IFN-λ, and they can travel between the liver and 
peripheral blood. The production of IFN-λ by DCs can inhibit 
HCV RNA replication in hepatocytes. However, HCV pro-
teins E2 and NS3 can also inhibit IFN-λ production by DCs. 
Hematopoietic cells express variable levels and splice variants of 
IFN-λR1, and conflicting results were obtained about the effect of 
IFN-λ treatment on these cells. HCV exposed DCs or DCs treated 
with IFN-λ display reduced stimulation of T cells by upregulat-
ing expression of PDL1 and enhanced proliferation of Tregs. 
Monocytes are responsive to IFN-λ treatment resulting in IL-12 
and IL-18 production. In turn, these cytokines can influence NK 
cell functions, and thus, IFN-λ is an important component of the 
innate immune response to HCV. The role of IFN-λ on CD4 and 
CD8 T cells as well as on B cells in the context of HCV remains 
understudied, but studies suggest that IFN-λ could modulate the 
CD4 Th1/Th2 balance and can also have a positive or negative 
impact on IgG production by B cells (Figure 2).
TYPe iii iFNs aND HCv-SPeCiFiC 
iMMUNiTY DURiNG PReGNaNCY
In HCV-infected women, a sharp decrease in HCV viral load 
is sometimes observed after childbirth, suggestive of a boost 
in the immune response following delivery (85, 86). It was 
recently demonstrated that beside a stronger T cell response, 
the presence of the favorable CC IFN-λ3 rs12979860 genotype 
was significantly associated with this high decrease in viral load 
(87). Considering the high linkage disequilibrium between IFN-
λ3 rs12979860 genotype and IFN-λ4 rs368234815 genotype, 
the IFN-λ4 was also associated with the decrease in viral load 
postpartum (87). It is well known that women’s immune system 
is altered through pregnancy to avoid a reaction against the fetus 
(88). It is postulated that the innate immune system will play a 
significant role against pathogens, while the adaptive immune 
responses are dampened by increased Tregs activity (89, 90). 
Another recent study showed that the expression of innate immu-
nity genes is enriched in postpartum women compared to control 
(91). Interestingly, ISGs level in women of the CT or TT IFN-λ3 
rs12979860 genotype remained elevated as late as 24 weeks after 
childbirth, while women with the CC IFN-λ3 genotype were 
comparable to non-pregnant controls (91). This reflects what was 
observed in the context of acute HCV where individuals with 
non-favorable CT or TT IFN-λ3 genotype had a higher baseline 
ISG expression in the liver.
iFN-λ DURiNG TReaTMeNT wiTH 
DiReCT-aCTiNG aNTiviRalS (Daa) aND 
HCv-RelaTeD liveR DiSeaSe
With the development of novel DAAs that are highly effective 
(~100%) against most genotypes, treatment has switched to IFN-
free regimens. Limited studies have indicated that polymorphism 
FiGURe 2 | interferon (iFN)-λ modulation of hematopoietic cells. In the hematopoietic compartment, dendritic cells (DCs) are the main producers of IFN-λ (1). 
The production of IFN-λ by DCs can inhibit hepatitis C virus (HCV) RNA replication in hepatocytes. However, HCV proteins E2 and NS3 can inhibit IFN-λ production 
by DCs. Hematopoietic cells express variable levels and splice variants of IFN-λR1, and conflicting results were obtained about the effect of IFN-λ treatment on 
these cells. HCV-exposed DCs or DC treated with IFN-λ display reduced stimulation of T cells through upregulation of PDL1 and enhanced proliferation of regulatory 
T cells (2). Monocytes are responsive to IFN-λ treatment resulting in interleukin (IL)-12 and IL-18 production (3). In turn, these cytokines will influence natural killer cell 
function (4), and thus, IFN-λ is an important component of the innate immune response to HCV. The role of IFN-λ on CD4 and CD8 T cells (5) as well as on B cells 
(6) in the context of HCV remains understudied, but studies suggest that IFN-λ could modulate the CD4 Th1/Th2 ratio and can also have a positive or negative 
impact on IgG production by B cells.
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in the IFN-λ region may influence the response to DAAs, especially 
if IFN is still used in the combination (92, 93). However, given the 
high rate of response to DAAs and the availability of multiple 
products on the market, IFN-λ has lost its predictive value, and 
testing for it before treatment is no longer recommended except 
in specific situations where a DAA and IFN combination may still 
be warranted (94).
Chronic HCV infection is associated with an increased risk 
of liver-related illness, such as fibrosis, cirrhosis, and hepatocel-
lular carcinoma (HCC). The link between IFN-λ polymorphisms 
and HCV-related liver disease is not completely clear and was 
reviewed in detail elsewhere (95). One study showed that the 
favorable CC IFN-λ3 rs12979860 allele, associated with better 
chance of HCV clearance, is also associated with higher blood 
ALT levels, indicative of increased liver inflammation. However, 
IFN-λ rs12979860 polymorphism was not associated with 
fibrosis progression in the same cohort (96). Another study did 
not find any association of the IFN-λ polymorphism with any 
of the observed associated liver illness (decompensated cirrhosis, 
HCC, liver-related death, and all-cause mortality) (97). On the 
other hand, Bochud et  al. demonstrated that particularly in 
non-genotype 1 HCV-infected individuals, the favorable IFN-λ 
alleles were associated with increased inflammation and higher 
fibrosis scores (98). In agreement with this, Eslam et al. observed 
a significant association between IFN-λ3 rs12979860 polymor-
phism and liver necroinflammatory activity, serum level of AST 
and ALT, as well as fibrosis score and progression (99). Once 
again the association was stronger in individuals infected with 
HCV genotype 3 than those infected with HCV genotype 1. Also, 
in patients carrying the IFN-λ4 rs368234815 unfavorable allele 
(ΔG), there was a correlation between the frequency of CD107a 
expressing cells and the serum ALT levels, suggestive of increased 
liver damage (49). In the context of HCC, two studies associated 
IFN-λ3 rs12979860 unfavorable CT or TT alleles with liver 
cirrhosis and the development of HCC in patients chronically 
infected with HCV (100, 101). However, this was not confirmed 
in two other independent studies in Japanese (102) or Italian 
cohorts (97). Finally, HCV-related liver disease is a multifactorial 
problem, and the independent association of genetic factors may 
not be a clear cut. Fortunately, with the development of highly 
effective DAAs, it is expected that these complications will be less 
frequent as SVR will be achievable in most patients.
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CONClUDiNG ReMaRKS
Type III IFNs exhibit strong antiviral activity, and yet, the expres-
sion of a functional IFN-λ4 protein was strongly associated with 
failure to clear HCV infection either spontaneously or after 
IFN-based treatment. A recent study suggested that humans sup-
press IFN-λ4 expression through various mechanisms and hence 
immune functions may be dependent on other type III IFNs 
(103). Data accumulated so far suggest that a higher baseline ISG 
expression level is associated with induction of a refractory state, 
where further IFN treatment has no beneficial effect. With the 
new era of anti-HCV IFN-free DAA therapies, the role of type 
III IFNs during therapy has become somewhat irrelevant but 
its role in mediating spontaneous clearance during acute HCV 
infection and modulating the cross-talk between innate and 
adaptive immunity remains highly pertinent. This is applicable 
not only for HCV infection but also for other viral infections and 
response to vaccines. Furthermore, the recently described role of 
type III IFN polymorphisms in driving immunity postpartum is 
just the tip of the iceberg as it will become increasingly relevant 
to mother–infant health and vertical transmission of various 
pathogens.
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